Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T-cell receptor (TCR) recognizing Dengue virus (DENV) peptide-MHC class I complexes is a specialized immune receptor found on the surface of CD8+ cytotoxic T lymphocytes. Its primary biological function is the surveillance and elimination of DENV-infected cells by recognizing viral peptides, predominantly derived from non-structural proteins such as NS3, NS4B, and NS5, which are presented by Human Leukocyte Antigen (HLA) class I molecules on the surface of antigen-presenting cells or infected host cells. Upon binding to its cognate peptide-MHC ligand, the TCR initiates an intracellular signaling cascade that results in the secretion of pro-inflammatory and antiviral cytokines, such as interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha), and the direct lysis of infected cells via the release of perforin and granzymes. While these responses are generally protective during primary infection, they are heavily implicated in the immunopathology of severe dengue (Dengue Hemorrhagic Fever and Dengue Shock Syndrome) through a phenomenon known as Original Antigenic Sin. In secondary infections with a different DENV serotype, preexisting cross-reactive memory T cells with low affinity for the new serotype may dominate the response, leading to ineffective viral control and a cytokine storm that increases vascular permeability. Therapeutic development focuses on vaccines, such as TAK-003 and Butantan-DV, which aim to elicit robust and high-avidity T-cell responses to conserved epitopes to provide cross-protective immunity across all four DENV serotypes.
Activation of CD8+ T cells through the specific recognition of viral peptides presented by MHC class I molecules, leading to the production of antiviral cytokines and the targeted destruction of infected cells.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor recognizing Dengue virus peptide-MHC class I complex (TCR-DENV-pMHC-I).